Table 1.
Participant characteristics
| Participant characteristic | Group‐1: Early continued ART (n = 7) | Group‐2: Suppressed viraemia and continued ART (n = 8) | Group‐3: Suppressed viraemia and interrupted (n = 23) |
|---|---|---|---|
| Treatment regimen | ABC, 3TC, LPV/ra | AZT, 3TC, LPV/r | AZT, 3TC, LPV/r |
| CHER Study arms | NA |
ART‐Def (n = 6) ART‐96W (n = 2)b |
ART‐40W (n = 15) ART‐96W (n = 6) Part B ART‐40W (n = 2)c |
| Age ART first initiated (days); median (IQR) | 5 (1.5 to 6.5) | 156.5 (110.3 to 256.8) | 55 (50.5 to 64.5) |
| Pre‐treatment log 10 HIV‐1 RNA load; median (IQR) | 3.1 (2.7 to 3.3) | 5.6 (5.3 to 5.9) | 5.3 (4.0 to 5.8) |
| Baseline ART HIV‐1 DNA copies/million cells; median (IQR) | 158 (40 to 398) | 1107 (468 to 2999) | 832 (363 to 1371) |
| CD4% nadird; median (IQR) | 40 (38.7 to 54.5) | 16.9 (14.0 to 19.1) | 21.8 (15.9 to 25.2) |
| Absolute CD4 count nadir cells/microlitred; median (IQR) | 1955 (1193 to 2064) | 505 (440.5 to 759.5) | 871 (577.5 to 1081.5) |
| Time interrupted (days); median (IQR) | ‐ | ‐ | 214 (141 to 284) |
| Age at last sample (years); median (IQR) | 1.0 (0.6 to 1.0) | 8.8 (1.3 to 9.7) | 9.2 (7.8 to 10.6) |
| CD4% (IQR) at last sample | 34 (28.5 to 37.5) | 34 (31 to 42) | 37 (35 to 39) |
| Absolute CD4 (IQR) (per microlitre) at last sample | 1920 (1440 to 2618) | 1032 (814 to 1199) | 1088 (847 to 1294) |
ART, antiretroviral therapy; CHER, Children with HIV early antiretroviral therapy trial; IQR, interquartile range.
aOriginal regimen was AZT, 3TC, NVP, with NVP replaced by LPV/r at 42 weeks of age and AZT replaced by ABC at 3 months of age; bgroup‐2 included 2 ART‐96W participants who were not interrupted as both had signs suggestive of HIV encephalopathy; cpart B of CHER had screening CD4 <25%; dbefore continued phase of treatment.